{
    "body": "Which biomarker is widely used in the diagnosis of Ewing sarcoma?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12783138"
    ], 
    "ideal_answer": [
        "CD99 is a hallmark marker for Ewing sarcoma and primitive neuroectodermal tumors."
    ], 
    "exact_answer": [
        "CD99"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015415", 
        "http://www.disease-ontology.org/api/metadata/DOID:4980", 
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012512", 
        "http://www.disease-ontology.org/api/metadata/DOID:3368"
    ], 
    "type": "factoid", 
    "id": "55376663bc4f83e82800000a", 
    "snippets": [
        {
            "offsetInBeginSection": 218, 
            "offsetInEndSection": 463, 
            "text": "half of B-LBL patients are negative for CD45 (leucocyte common antigen, LCA), a widely used marker for the diagnosis of lymphoma, and a significant portion express CD99, a marker for Ewing's sarcoma (ES) or primitive neuroectodermal tumor (PNET)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783138", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 208, 
            "offsetInEndSection": 463, 
            "text": "Moreover, half of B-LBL patients are negative for CD45 (leucocyte common antigen, LCA), a widely used marker for the diagnosis of lymphoma, and a significant portion express CD99, a marker for Ewing's sarcoma (ES) or primitive neuroectodermal tumor (PNET)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783138", 
            "endSection": "abstract"
        }
    ]
}